STAAR Surgical director granted 11,145 stock options

STAAR Surgical director Neal C. Bradsher reported a new stock option grant as director compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

STAAR Surgical director Neal C. Bradsher reported a new stock option grant as director compensation. He received options for 11,145 shares of common stock at an exercise price of $29.12 per share, expiring on June 18, 2036.

The new options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, contingent on his continued service. Bradsher also holds previously granted options covering 7,524 underlying shares at an exercise price of $18.46 per share, which are currently exercisable.

Insider Trade Summary

Grant/Award: 11,145 shares

Grant/Award 2 txns

Insider Bradsher Neal C

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	OPTION TO PURCHASE COMMON STOCK	11,145	$0.00	$0.00
holding	OPTION TO PURCHASE COMMON STOCK	--	--	--

Holdings After Transaction: OPTION TO PURCHASE COMMON STOCK — 18,669 contracts for 7,524 underlying shares (Direct)

Footnotes (3)

F1. These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.
F2. These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.
F3. These options are currently exercisable.

Key Figures

New option grant size: 11,145 shares New option exercise price: $29.12 per share New option expiration: June 18, 2036 +3 more

6 metrics

New option grant size 11,145 shares Options to purchase common stock granted June 18, 2026

New option exercise price $29.12 per share Exercise price for 11,145-share option grant

New option expiration June 18, 2036 Expiration date of newly granted options

Existing options underlying shares 7,524 shares Underlying common stock for existing options

Existing options exercise price $18.46 per share Exercise price of existing currently exercisable options

Existing options expiration March 5, 2036 Expiration date of existing options

Key Terms

Amended and Restated Omnibus Equity Incentive Plan, director compensation, vest and become exercisable, underlying security, +1 more

5 terms

Amended and Restated Omnibus Equity Incentive Plan financial

"pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended"

director compensation financial

"These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation"

vest and become exercisable financial

"These options will vest and become exercisable on the earlier of: (a) June 18, 2027"

underlying security financial

"underlying_security_title": "COMMON STOCK","underlying_security_shares": "11145.0000""

stock option grant financial

"These options were granted to the Reporting Person by the Issuer on June 18, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Neal C. Bradsher report in this STAAR Surgical (STAA) Form 4?

Neal C. Bradsher reported receiving a grant of stock options for 11,145 STAAR Surgical shares. These options were awarded as director compensation under the company’s Amended and Restated Omnibus Equity Incentive Plan.

What are the key terms of Neal Bradsher’s new STAAR Surgical stock options?

Bradsher’s new options cover 11,145 shares at an exercise price of $29.12 per share. They expire on June 18, 2036, providing a long-term incentive tied to STAAR Surgical’s share performance.

When do Neal Bradsher’s newly granted STAAR Surgical options vest?

The options vest on the earlier of June 18, 2027 or the next STAAR Surgical annual shareholder meeting after the June 18, 2026 grant date. Vesting requires his continuous service as a director with the company.

Does Neal Bradsher hold other STAAR Surgical stock options besides this new grant?

Yes. He also holds options tied to 7,524 STAAR Surgical common shares at an $18.46 exercise price. According to the disclosure, these earlier options are already exercisable and expire on March 5, 2036.

Is Neal Bradsher’s Form 4 transaction a market buy or sell of STAAR Surgical shares?

No market buy or sell is reported. The Form 4 reflects a grant of stock options as director compensation, not an open-market purchase or sale of STAAR Surgical common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 07:36 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bradsher Neal C

(Last)

(First)

(Middle)

C/O BROADWOOD CAPITAL, INC.

156 WEST 56TH STREET, 3RD FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
OPTION TO PURCHASE COMMON STOCK	$29.12	06/18/2026		A		11,145		⁽¹⁾	06/18/2036	COMMON STOCK	11,145	$0⁽²⁾	11,145	D
OPTION TO PURCHASE COMMON STOCK	$18.46							⁽³⁾	03/05/2036	COMMON STOCK	7,524		7,524	D

Explanation of Responses:

1. These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.

2. These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.

3. These options are currently exercisable.

	/s/ Neal C. Bradsher	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR